| March 2005 |
SymBio Pharmaceuticals Limited established at Nishi-Shimbashi, Minato-ku, Tokyo |
| July 2005 |
Head office relocates to Shimbashi, Minato-ku, Tokyo |
| December 2005 |
License Agreement finalized with Astellas Pharma GmbH for SyB L-0501 (bendamustine) development & commercialization rights in Japan |
| March 2006 |
Manufacturer's License (packaging, labeling and storage) obtained from Tokyo Metropolitan Government |
| March 2007 |
License Agreement finalized with Astellas Deutschland GmbH for SyB L-0501 (bendamustine) development & commercialization rights in China (HK), Taiwan, Korea and Singapore |
| August 2008 |
License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Japan |
| March 2009 |
SymBio Pharmaceuticals concludes Sublicense Agreement with Cephalon, Inc. for development and commercialization rights of bendamustine hydrochloride in China (HK) |
| May 2009 |
License Agreement finalized with Eisai Co., Ltd. for co-development and commercialization rights of SyB L-0501 (bendamustine) in Korea and Singapore |
| October 2010 |
Received Domestic Manufacturing and Marketing Approval for Anticancer Agent TREAKISYM |
| December 2010 |
Launched domestic sales of anticancer agent TREAKISYM |
| July 2011 |
Onconova and SymBio Pharmaceuticals complete License Agreement for SyB L-1101/SyB C-1101 |
| October 2011 |
Listed on Osaka Securities Exchange JASDAQ Growth Market |
| November 2014 |
Head office relocates to Toranomon, Minato-ku, Tokyo |
| May 2016 |
SymBio Pharma USA, Inc. established at Menlo Park, California, USA |
| August 2016 |
Approval for Domestic Manufacturing and Marketing of Anticancer Agent TREAKISYM for Additional Indication of Chronic Lymphocytic Leukemia |
| December 2016 |
SymBio Pharmaceuticals announces the NDA approval of TREAKISYM ®(bendamustine) for the additional indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma in Japan |
| September 2017 |
Eagle Pharmaceuticals (NASDAQ: EGRX) and SymBio Pharmaceuticals completed License Agreement for bendamustine liquid formulations (RTD Injection and RI Injection) development & commercialization rights in Japan *RTD: Ready-to-dilute, RI: Rapid Infusion |
| July 2018 |
TREAKISYM®(bendamustine) has been newly included as a standard-of-care option in the Guidelines for Tumors of Hematopoietic and Lymphoid Tissues 2018 |
| September 2019 |
SymBio Pharmaceuticals obtained from Chimerix (NASDAQ:CMRX) the exclusive worldwide rights to develop, manufacture, and commercialize the antiviral drug brincidofovir (BCV) excluding the prevention and treatment of smallpox |
| September 2020 |
SymBio Pharmaceuticals receives approval of TREAKISYM®Ready-To-Dilute (RTD) formulation |
| December 2020 |
Commencement of in-house sales of the anti-cancer agent TREAKISYM® |
| January 2021 |
Market Launch of TREAKISYM®Ready-To-Dilute (RTD) Formulation |
| March 2021 |
SymBio Pharmaceuticals receives approval of TREAKISYM ®(bendamustine) in combination with rituximab, and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma |
| April 2021 |
SymBio Pharmaceuticals receives approval of TREAKISYM®Ready-To-Dilute (RTD) Formulation in combination with rituximab ,and in combination with rituximab and polatuzumab vedotin for relapsed or refractory diffuse large B-cell lymphoma |
| February 2022 |
SymBio Pharmaceuticals receives approval of 10-minute Rapid Infusion (RI) administration of the TREAKISYM®Liquid Formulation |
| December 2023 |
Head office relocates within Toranomon, Minato-ku, Tokyo |